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Patients Characteristics
Case Diagnosis CD3/kg CD34/kg Chimeras Acute GVHD Status/time post-transplant
1 ALL in 3 CR 2x106 18x106 86% No Alive-Remission/ 9 months
2 ALL in 3 CR 5x105 10x106 100% No Alive-Remission/ 2 months
3 ALL in 2 CR 2x105 12x106 13% No Alive-Remission/ 2 months
4 AML in 2 CR 6x105 6.9x106 100% Skin grade III Relapse at 3 months/
5 Sickle cell disease 14x105 7.8x106 Pending No Alive/1 month
6 Sickle cell disease/ Thalasemia 13x105 8.6x106 86% No Alive/ 2 month
7 ALL high risk in 1 CR 3.4x105 12x106 100% Skin grade I Alive-Remission/ 4 months
8 ALL in 2 CR 8.6x105 6.7x106 90% Skin and intestine II Alive-Remission/ 4 months.
9 AML in 2 CR 2.1x106 11.2x106 — — —
10 ALL in 2 CR 1.2 x106 15 x106 — — —
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stantial portion of the remaining patients. Haploidentical HCT is
a viable alternative since almost every patient has at least a haplo-
type-sharing parent, child, or sibling available to donate stem cells,
but it has been limited by high risk of severe graft-versus-host disease
(GVHD), graft rejection, life-threatening infections, and relapse—
all of which are partially caused by intensive immunosuppressive
therapy and T-cell depletion.
Patients and methods: Between January and October 2009 all
pediatric patients (ten patients) in our center who needed trans-
plant without a suitable donor were included in our haploident-
ical transplant program. The median age of the patients was 7
years (range between 2 and 11 years), five boys and five girls.
The HLA compatibility was 7/10 in one patient, 8/10 in one pa-
tient and 5/10 in 8 patients. In all the cases the mother was the
donor.
The patients received the following conditioning regimen in out-
patient basis, thymoglobulin (from day -10 to day -7), cyclophospha-
mide (from day -6 to day -3), fludarabine (from day -6 to day -3), (on
day -2), cyclosporine (begin day -1), stem cells infusion (day 0).
GVHD was with prednisone, cyclosporine and low doses of metho-
trexate, and, depending on the T cell dose, mycophenolate was used.
More characteristics are show in table 1.
Results: Eight of 10 patients could be evaluated. Engraftment was
achieved in all patients. However, two of them rejected afterwards.
One patient received a second cells infusion. Three patients pre-
sented mild GVHD. A bone marrow relapse happened in a patient
with acute myelogenous leukemia, and a patient die for transplant
lymphoproliferative disorder without neoplastic activity and with
a 100% chimerism.
Conclusions: We have demonstrated in a small group of patients
that the use of stem cells from haploidentical parental donors should
be strongly considered in children who need transplantation but lack
of a match-related donor. Long-term follow-up and a large number
of patients for a better analysis are needed.376
LATE ONSET INTESTINAL PERFORATION IN THE SETTING OF POST-
TRANSPLANT MIRCOANGIOPATHY: A REPORT OF TWO CASES
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Background: Intestinal perforation in the setting of post-transplant
microangiopathy (TMA) is a very rare event and might be considered
a terminal event of intestinal microangiopathy (i-TMA), a rather
rarely recognized post-transplant complication, as it overlaps with
the more common intestinal graft-versus-host-disease (GVHD).
Cases of i-TMA described in literature occurred within with first
100-days post-transplant or shortly thereafter. The aim of this study
is to describe two cases of late onset intestinal perforation thatoccurred in the setting of systemic microangiopathy more than
a year post allogeneic transplant.
Results: One patient presented 380 days post matched unrelated
allogeneic transplantation with acute respiratory distress second-
ary to diffuse alveolar hemorrhage. Five days later she developed
constipation and abdominal distension. An ultrasound of the ab-
domen revealed portal venous gas and multiple loops of dilated
fluid filled bowel concerning for bowel ischemia. She underwent
exploratory laparatomy and subsequent subtotal colectomy. Path-
ologic examination confirmed ischemic necrosis. She fulfilled the
criteria for TMA diagnosis and was started on plasmapheresis
and rituximab. Tacrolimus was discontinued prior to her admis-
sion. Despite these measures, the patient passed away from pro-
gressive TMA 17 days after surgery. The second patient
presented two years post matched unrelated donor transplant
with abdominal pain in the setting of sepsis. Admission CT
scan revealed perisplenic gas and fluid collection concerning for
possible abscess. An exploratory laparatomy revealed diffuse is-
chemic large bowel requiring a hemicolectomy. Pathologic exam-
ination was consistent with chronic ischemic changes with
intestinal mucosal fibrosis and focal ulceration. He also fulfilled
the criteria for diagnosis of TMA and calcineurin inhibitor was
discontinued. Ultimately, he died of sepsis and unresponsive
TMA. Both patients, prior to their presentation, were treated
for chronic GVHD of the liver and lower gastrointestinal tract
with steroids in addition to tacrolimus. The final pathologic
exam did not show evidence of GVHD in the first case, but
did show crypt apoptosis and crypt abscess in the second case,
raising the possibility of associated GVHD.
Conclusion: Intestinal perforation in the setting of TMA can oc-
cur as a late post-transplant complication, and is associated with
poor response to treatment secondary to refractory mircoangio-
pathy.377
RESPONSES TO A QUESTIONNAIRE FOR PATIENTS ABOUT BONE MAR-
ROW TRANSPLANTATION
Van Hoef, M.E.H.M. Transplant Creations, Amsterdam, Noord Holland,
Netherlands
Introduction: In the context of our focus on treatment by hemato-
poietic cell transplantation as part of therapy a questionnaire was de-
veloped to offer patients visiting the website or link at a public sites to
respond.
Method:A survey was prepared containing 20 questions, 6 related to
general responders characteristics, 10 to autologous and allogeneic
transplantation, and 4 to donation of bone marrow, interest in edu-
cation about transplantation and donation for clinical research or
treatment by transpant. All yes/no questions also had the option
not applicable or uncertain.
The results were analysed as % of all responders and % of re-
sponders to a question. Herein we present as % of all respondsers.
Table. Patient Characteristics
Patient Age/Sex Pre-SCT Karyotype
Time from
Dx to SCT SCT type/ Prep/ GVHD px Follow-up Post-SCT Genetic Studies
1 46 M 46,XY,t(9;22)[12],
47,XY,18 [2], 46,XY[3],
46,XY,1Y,-7[3]
16 months MSD/ Bu1Cy / CSA1MTX 16 months Bcr-Abl PCR: negative,
FISH for -7: negative
2 48 F 46,XX,t(9;22)[17], 45,XX,-7[3] 19 months MUD/ Bu1Cy / Tacrolimus1MTX 17 months Bcr-Abl PCR: negative
3 48 M 46,XY[3], 46,XY,t(9;22)[9],
47,XY,18[1], 45,XY,-7[7]
30 months MUD/ Bu1Cy / CSA1MTX 20 months Bcr-Abl PCR: negative
Abbreviations: Dx, diagnosis, M, male; F, female; SCT, stem cell transplant; Prep, preparative regimen; GVHD px, graft versus host disease prophylaxis;
CSA, cyclosporine; MTX, methotrexate; MSD, matched sibling donor; MUD, matched unrelated donor; PCR, polymerase chain reaction; FISH; fluores-
cence in situ hybridization.
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vey, 100 could read dutch and 7 filled out the english version. 69%
were women. 45% were patients, 24% family members, 21% were
neither patient nor family member. 19% had leukemia, 7% lym-
phoma, 10% multiple myeloma, 22% breast cancer, 14% another
type of cancer and 13% had no cancer. 39% had developed cancer
in the past three years.
38% of responders knew what autologous and 42% what alloge-
neic transplantation is. 29% knew that autologous and 29% that al-
logeneic transplants were possible treatment options. 21% had
spoken with a doctor about autologous and 20% about allogeneic
transplant. 9% had been treated by autologous and 9% by allogeneic
transplantation. 26% were interested to receive more information
about transplantation.
55% was aware that bone marrow can be donated. The cost
estimate was in all but two responders far below the actual costs
of the procedures. Only 2% of responders was interested to
make a donation to support research in transplantatation and
24% were uncertain. 42% were not interested to donate for
research.
Discussion: Herein results are presented of responses to a website
questionnaire. Through time 107 people have responded and only
45% were patient. This is a small percentage of patients who have
seen the invitation to respond either at the website or a public site.
Our survey shows that bone marrow transplantation is considered
a treatment and not research.378
SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION OF PATIENTS
WITH CML AND MONOSOMY 7
Hill, B.T.1, Agha, M.A.2, Kalaycio, M.1 1Cleveland Clinic, OH;
2University of Pittsburgh Cancer Institute, PA
Patients with chronic myeloid leukemia (CML) whose Phila-
delphia chromosome-positive [Ph+] cells harbor additional cyto-
genetic abnormalities have been cured with allogeneic stem cell
transplantation (SCT). Although abnormalities in Ph- cells are
often transient and innocuous, loss of chromosome 7 is a harbin-
ger of poor-prognosis myelodysplastic syndrome (MDS) and, ul-
timately, transformation to acute myeloid leukemia (AML). SCT
is potentially curative for patients with coexistent CML and
MDS with monosomy 7, however, there are no reported data
on outcomes of such patients who have undergone SCT. We
retrospectively identified three patients with CML who subse-
quently developed monosomy 7 in Ph- cells. All three were suc-
cessfully treated with SCT. Their characteristics and outcome
are listed in the Table. All three were initially treated with
imatinib, but had suboptimal responses with persistent myelo-
suppression and subsequent development of monosomy 7 in
Ph- cells. Patients with CML who have suboptimal responses
and myelosuppression during therapy with imatinib are at risk
for development of monosomy 7 in Ph- cells. Early identifica-
tion of such patients allows for potentially curative SCT beforethe development of AML. We conclude that coexistent Ph+
CML and Ph- MDS with monosomy 7 can be successfully
treated with allogeneic SCT. Further follow-up is needed to de-
termine long-term outcomes.379
ISOLATED EPSTEIN-BARR VIRUS-INDUCED CENTRAL NERVOUS SYSTEM
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER DESPITE
NEGATIVE SERUM PCR
Milani, C.1, Abourahma, R.3, Welch, P.2, Roy, T.2, Pojani, J.2,
Al-Homsi, A.-S.2 1Brown University, Providence, RI; 2Roger Williams
Medical Center, Boston University, Providence, RI; 3Memorial Hospital,
Providence, RI
Esptein-Barr virus (EBV)-induced post-transplant lymphopro-
liferative disorder (PTLPD) is a well recognized complication
of hematopoietic and solid organ transplantation. Central ner-
vous system (CNS) localization in the absence of systemic dis-
ease is rare. In addition, most cases are associated with rising
EBV viral load in the serum. Indeed, positive EBV PCR assay
on the serum was found to have a negative predictive value of
93%. Therefore, clinicians have been relying on such testing
to monitor patients at risk and administer preemptive therapy
with rituximab.
We report a patient who developed CNS space-occupying le-
sion six months following bone marrow transplantation from an
unrelated donor with A allele mismatch for recurrent acute mye-
logenous leukemia. The patient conditioning regimen had in-
cluded fludarabine, melphalan, and rabbit ATG. The patient
course had been significant for severe acute graft-versus-host dis-
ease requiring multiple immunosuppressive agents including ritux-
imab. The lesion was biopsied and proven to represent EBV
positive diffuse large B cell-lymphoma. An extensive staging
work-up failed to reveal any evidence of systemic disease. All pre-
vious studies on the serum for EBV by PCR had been negative as
was repeat testing at the time of diagnosis. EBV however was de-
tected in the CSF.
The discovery of an EBV-driven isolated CNS PTLD in our pa-
tient is unusual in that there was no evidence of EBV in the periph-
eral blood by PCR. Two similar cases have been reported in the
literature.
The nature of this phenomenon is uncertain. One plausible ex-
planation is the effectiveness of rituximab in clearing the virus
from the peripheral blood but not from the CNS given its
poor blood-brain barrier penetration. If this was the case, one
might fear an increase in the incidence of CNS localization of
PTLD as clinicians increasingly rely on the use of rituximab in
face of rising EBV viral load in the peripheral blood. In summa-
tion we believe that clinicians should be aware of the potential
for CNS PTLD in the absence of PCR-evidence of EBV reacti-
vation in peripheral blood in patients treated with rituximab. Ef-
forts must continue to develop alternative approaches to
preemptive treatments of EBV reactivation such as adoptive
immunotherapy.
